ProfileGDS5678 / 1449014_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 87% 87% 85% 85% 87% 84% 85% 85% 86% 85% 85% 84% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6457487
GSM967853U87-EV human glioblastoma xenograft - Control 26.7441387
GSM967854U87-EV human glioblastoma xenograft - Control 36.6859587
GSM967855U87-EV human glioblastoma xenograft - Control 46.4735285
GSM967856U87-EV human glioblastoma xenograft - Control 56.3468985
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5047687
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.1297584
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3239685
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3105485
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.5190486
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4090385
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4699185
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2326284
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2295984